| Name | Title | Contact Details |
|---|
Valley Medical Center (VMC), also known as King County Public Hospital District No. 1, is located in Renton, WA. The Medical Center’s service area includes the communities of Renton, Kent, Tukwila, Covington, Maple Valley, Auburn, Newcastle and the surrounding environs. A 303-bed acute care hospital and clinic network, VMC is committed to providing safe, quality compassionate care and has done so for more than 63 years. Seattle magazine named VMC the #1 non-profit in the state for 2011, the Puget Sound Business Journal honored VMC as “Washington’s Best Workplace” for 2011 in the extra large company category, and for ten consecutive years VMC has been named a “Best Workplace” by regional publications. For the past four out of four years VMC has been named a “Best Place to Work in Healthcare” in the nation by Modern Healthcare magazine, including twice achieving a top 10 ranking. Valley Medical Center is a component entity of UW Medicine.
Medaudit Services Inc is a Midland, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
OtisMed Corporation is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Human Care HC Sweden AB is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.